Evaluation of therapeutic response to concurrent chemoradiotherapy in patients with cervical cancer using diffusion-weighted MR imaging

Journal of Magnetic Resonance Imaging

Volumn 37, Issue 1, 2013, Pages 187-193

  Kim, Hyun Su ^a   Kim, Chan Kyo ^a   Park, Byung Kwan ^a   Huh, Seung Jae ^a   Kim, Bohyun ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

apparent diffusion coefficient; biomarker; concurrent chemoradiotherapy; diffusion weighted MRI; uterine cervical neoplasms

Indexed keywords

CISPLATIN; FLUOROURACIL; GADOBUTROL; GADOLINIUM PENTETATE;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONCURRENT CHEMORADIOTHERAPY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; LYMPH NODE METASTASIS; PELVIS LYMPH NODE; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT RESPONSE; TUMOR VOLUME; UTERINE CERVIX CANCER; UTERINE FUNDUS; VULVA;

ADULT; AGED; CHEMORADIOTHERAPY; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; MEDICAL ONCOLOGY; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; UTERINE CERVICAL NEOPLASMS;

EID: 84872857291     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.23804     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Monk BJ, Tewari KS, Koh WJ,. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol 2007; 25: 2952-2965.
3. Souhami L, Seymour R, Roman TN, et al. Weekly cisplatin plus external beam radiotherapy and high dose rate brachytherapy in patients with locally advanced carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1993; 27: 871-878.
4. Nam H, Park W, Huh SJ, et al. The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI. Gynecol Oncol 2007; 107: 320-325.
5. Wagenaar HC, Trimbos JB, Postema S, et al. Tumor diameter and volume assessed by magnetic resonance imaging in the prediction of outcome for invasive cervical cancer. Gynecol Oncol 2001; 82: 474-482.
6. Eifel PJ, Morris M, Wharton JT, Oswald MJ,. The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1994; 29: 9-16.
7. Kapp KS, Stuecklschweiger GF, Kapp DS, et al. Prognostic factors in patients with carcinoma of the uterine cervix treated with external beam irradiation and IR-192 high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 1998; 42: 531-540.
8. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
9. Lee KC, Moffat BA, Schott AF, et al. Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res 2007; 13: 443-450.
10. Pickles MD, Gibbs P, Lowry M, Turnbull LW,. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 2006; 24: 843-847.
11. Britten RA, Evans AJ, Allalunis-Turner MJ, Franko AJ, Pearcey RG,. Intratumoral heterogeneity as a confounding factor in clonogenic assays for tumour radioresponsiveness. Radiother Oncol 1996; 39: 145-153.
12. Mannelli L, Patterson AJ, Zahra M, et al. Evaluation of nonenhancing tumor fraction assessed by dynamic contrast-enhanced MRI subtraction as a predictor of decrease in tumor volume in response to chemoradiotherapy in advanced cervical cancer. AJR Am J Roentgenol 2010; 195: 524-527.
13. Mayr NA, Yuh WT, Zheng J, et al. Prediction of tumor control in patients with cervical cancer: analysis of combined volume and dynamic enhancement pattern by MR imaging. AJR Am J Roentgenol 1998; 170: 177-182.
14. Zahra MA, Tan LT, Priest AN, et al. Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer. Int J Radiat Oncol Biol Phys 2009; 74: 766-773.
15. Kim CK, Park BK, Kim B,. Diffusion-weighted MRI at 3 T for the evaluation of prostate cancer. AJR Am J Roentgenol 2010; 194: 1461-1469.
16. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-125.
17. Hamstra DA, Rehemtulla A, Ross BD,. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 2007; 25: 4104-4109.
18. Harry VN,. Novel imaging techniques as response biomarkers in cervical cancer. Gynecol Oncol 2010; 116: 253-261.
19. Song I, Kim CK, Park BK, Park W,. Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T. AJR Am J Roentgenol 2010; 194: W477-W482.
20. Harry VN, Semple SI, Gilbert FJ, Parkin DE,. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol Oncol 2008; 111: 213-220.
21. Liu Y, Bai R, Sun H, Liu H, Zhao X, Li Y,. Diffusion-weighted imaging in predicting and monitoring the response of uterine cervical cancer to combined chemoradiation. Clin Radiol 2009; 64: 1067-1074.
22. Winer-Muram HT, Jennings SG, Tarver RD, et al. Volumetric growth rate of stage I lung cancer prior to treatment: serial CT scanning. Radiology 2002; 223: 798-805.
23. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000; 92: 2029-2036.
24. Dzik-Jurasz A, Domenig C, George M, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002; 360: 307-308.
25. Nilsen L, Fangberget A, Geier O, Olsen DR, Seierstad T,. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Acta Oncol 2010; 49: 354-360.
26. Kamel IR, Reyes DK, Liapi E, Bluemke DA, Geschwind JF,. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2007; 18: 49-56.
27. Mardor Y, Pfeffer R, Spiegelmann R, et al. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 2003; 21: 1094-1100.
28. Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B,. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol 2009; 193: 1044-1052.
29. Buijs M, Kamel IR, Vossen JA, Georgiades CS, Hong K, Geschwind JF,. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol 2007; 18: 957-963.
30. Vossen JA, Kamel IR, Buijs M, et al. Role of functional magnetic resonance imaging in assessing metastatic leiomyosarcoma response to chemoembolization. J Comput Assist Tomogr 2008; 32: 347-352.
31. Naganawa S, Sato C, Kumada H, Ishigaki T, Miura S, Takizawa O,. Apparent diffusion coefficient in cervical cancer of the uterus: comparison with the normal uterine cervix. Eur Radiol 2005; 15: 71-78.
32. McVeigh PZ, Syed AM, Milosevic M, Fyles A, Haider MA,. Diffusion-weighted MRI in cervical cancer. Eur Radiol 2008; 18: 1058-1064.